TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Roth Capital to "Strong-Buy" Rating

Roth Capital upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI - Free Report) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports.

A number of other equities research analysts also recently issued reports on TLSI. Roth Mkm initiated coverage on TriSalus Life Sciences in a research report on Monday. They set a "buy" rating and a $11.00 price target for the company. Oppenheimer initiated coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They issued an "outperform" rating and a $10.00 target price for the company. Northland Capmk raised TriSalus Life Sciences to a "strong-buy" rating in a research report on Friday, October 25th. Finally, Northland Securities initiated coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an "outperform" rating and a $12.50 target price for the company. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $12.25.

TriSalus Life Sciences Price Performance

TLSI stock traded up $0.10 during trading on Monday, reaching $4.58. 53,618 shares of the stock traded hands, compared to its average volume of 38,330. The business's 50 day moving average price is $4.40 and its 200-day moving average price is $5.90. TriSalus Life Sciences has a 52-week low of $3.32 and a 52-week high of $10.42. The firm has a market capitalization of $139.65 million, a PE ratio of -1.79 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $7.36 million during the quarter. On average, equities research analysts predict that TriSalus Life Sciences will post -1.51 earnings per share for the current year.

Insider Activity at TriSalus Life Sciences

In other news, CEO Mary T. Szela acquired 7,520 shares of the business's stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the purchase, the chief executive officer now directly owns 377,382 shares of the company's stock, valued at $1,962,386.40. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 32.80% of the stock is currently owned by company insiders.

Institutional Trading of TriSalus Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wolverine Asset Management LLC acquired a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $240,000. Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences during the 2nd quarter valued at $1,184,000. Finally, Duquesne Family Office LLC boosted its stake in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after purchasing an additional 110,966 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.